Search

everythinglearnresearchcommunity

for

Search:↓

Liquid minoxidil makes hair sticky and stiff; users suggest oral minoxidil or minoxidil foam as alternatives. Applying minoxidil four hours before showering can help with absorption.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.

A young male in his twenties discusses hair loss, mentioning the use of Minoxidil, topical finasteride, and occasional derma rolling. He inquires about scalp inflammation, fibrosis, and the potential benefits of magnesium oil and scalp massages for improving blood flow and hair health.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Finasteride can reduce DHT in the genitalia, potentially causing side effects like reduced erections and penile fibrosis. Using PDE5 inhibitors like Tadalafil or Sildenafil may help maintain penile health and prevent fibrosis.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

8 months post hair transplant, OP experiences asymmetrical shedding despite using finasteride and starting minoxidil. The doctor suggests it might correct itself or be due to transplant trauma, recommending a wait-and-see approach.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The user experienced excessive bleeding during microneedling after consuming caffeine and THC, and is unsure if they should continue with the same routine. They are seeking advice on whether the bleeding is a cause for concern.

A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

A female user is experiencing severe hair loss, especially at the crown and front, with broken and dull hair despite using Moroccan oil, shea moisture shampoo, and coconut oil. She seeks recommendations for a clinic or doctor as previous doctors attributed the issue to stress but offered no solutions.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.